Simple jQuery Dropdowns
Please use this identifier to cite or link to this item: http://repository.li.mahidol.ac.th/dspace/handle/123456789/11420
Title: Phase i study of sunitinib and irinotecan for patients with recurrent malignant glioma
Authors: David A. Reardon
James J. Vredenburgh
April Coan
Annick Desjardins
Katherine B. Peters
Sridharan Gururangan
Sith Sathornsumetee
Jeremy N. Rich
James E. Herndon
Henry S. Friedman
Duke University School of Medicine
Mahidol University
Cleveland Clinic Foundation
Keywords: Biochemistry, Genetics and Molecular Biology;Medicine;Neuroscience
Issue Date: 1-Dec-2011
Citation: Journal of Neuro-Oncology. Vol.105, No.3 (2011), 621-627
Abstract: We determined the maximum tolerated dose (MTD) and dose-limiting toxicities (DLT) of the oral vascular endothelial growth factor receptor (VEGFR) inhibitor, sunitinib, when administered with irinotecan among recurrent malignant glioma (MG) patients. For each 42-day cycle, sunitinib was administered once a day for four consecutive weeks followed by a 2 week rest. Irinotecan was administered intravenously every other week. Each agent was alternatively escalated among cohorts of 3-6 patients enrolled at each dose level. Patients on CYP3A-inducing anti-epileptic drugs were not eligible. Twenty-five patients with recurrent MG were enrolled, including 15 (60%) with glioblastoma (GBM) and 10 (40%) with grade 3 MG. Five patients progressed previously on bevacizumab and two had received prior VEGFR tyrosine kinase inhibitor therapy. The MTD was 50 mg of sunitinib combined with 75 mg/m 2 of irinotecan. DLT were primarily hematologic and included grade 4 neutropenia in 3 patients and one patient with grade 4 thrombocytopenia. Non-hematologic DLT included grade 3 mucositis (n = 1) and grade 3 dehydration (n = 1). Progression-free survival (PFS)-6 was 24% and only one patient achieved a radiographic response. The combination of sunitinib and irinotecan was associated with moderate toxicity and limited anti-tumor activity. Further studies with this regimen using the dosing schedules evaluated in this study are not warranted. © 2011 Springer Science+Business Media, LLC.
URI: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=82955232920&origin=inward
http://repository.li.mahidol.ac.th/dspace/handle/123456789/11420
ISSN: 15737373
0167594X
Appears in Collections:Scopus 2011-2015

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.